| dc.description.abstract | The emergence of the Covid-19 virus outbreak, brings several negative impacts on
people health and the economy of which the recovery will take a quite long time. The
initial action taken by many countries is to improve the quality of their respective
health, including producing a Covid-19 vaccine. In Indonesia, the Government has
assigned PT Bio Farma, which is a State-Owned Enterprise, to procure Covid-19
vaccines, in accordance with Presidential Regulation Number 99 of 2020 concerning
Vaccine Procurement and Vaccine Implementation in the Context of Eradicating
Corona Virus Disease 2019 (Covid19 Pandemic. This study examines the suitability
of Antitrust Immunity in the assignment of COVID-19 vaccine procurement to PT.
Biofarma. Furthermore, there is Presidential Regulation Number 99 of 2020
concerning Vaccine Procurement and Vaccine Implementation in the Context of
Eradicating the 2019 Corona Virus Disease (Covid-19) Pandemic, including
Antitrust Immunity. Antitrust immunity is a exceptions to the prohibition of
monopolistic practices for business actors with certain criteria. Provisions that are
excluded from the application include Article 50 letter a and Article 51 of Law
Number 5 of 1999. Based on this arrangement, the Covid-19 Vaccine Assignment in
Indonesia should only focus on PT Bio Farma PT Bio Fa RMA is a BUMN that is
appointed directly based on the applicable laws and regulations by taking into
account the fulfillment of community needs. Furthermore, if in carrying out the
assignment PT Bio Farma requires goods and or services, then it should be done by
tender. | en_US |
